Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study

Venous thromboembolism (VTE) is common in patients with terminal cancer. Current treatment practice with warfarin has a high incidence of complications, including bleeding, poor control and recurrent VTE. Long-term low-molecular-weight heparin (LMWH) therapy is safer and more efficacious in this pat...

Full description

Saved in:
Bibliographic Details
Published in:Palliative medicine 2005-04, Vol.19 (3), p.197-201
Main Authors: Noble, Simon IR, Finlay, I G
Format: Article
Language:English
Subjects:
Acceptability
Adult
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Anticoagulants - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Cancer
Clinical death. Palliative care. Organ gift and preservation
Deep vein thrombosis
Female
Heparin
Heparin, Low-Molecular-Weight - therapeutic use
Humans
Intensive care medicine
Male
Medical sciences
Middle Aged
Neoplasms - complications
Palliative care
Palliative Care - methods
Patient Satisfaction
Patients
Pharmacology. Drug treatments
Qualitative research
Quality of life
Thromboembolism - etiology
Thromboembolism - prevention & control
Treatment
Venous Thrombosis - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Venous thromboembolism (VTE) is common in patients with terminal cancer. Current treatment practice with warfarin has a high incidence of complications, including bleeding, poor control and recurrent VTE. Long-term low-molecular-weight heparin (LMWH) therapy is safer and more efficacious in this patient group, but there are concerns that daily therapy may have a negative impact on quality of life. A qualitative study was carried out to determine whether LMWH was acceptable in palliative care patients, both in the community and in-patient units. Forty palliative care patients receiving LMWH for VTE were interviewed. Participants found LMWH to be an acceptable intervention, allowing them freedom from blood tests and optimism regarding their care. It was considered a preferable therapy to warfarin, which had a negative impact on participant's quality of life. The findings of this study support the use of LMWH, first line in the treatment of established VTE in the palliative care setting.
ISSN:0269-2163
1477-030X
DOI:10.1191/0269216305pm1008oa